We confirmed that the coverage of published GWAS for asthma performed in European populations to date has been insufficient for ADAM33 (<30%), even in a best-case scenario using the HapMap phase 2 data as a reference for comparisons (Table S7). Here, ADAM33 is linked to asthma.